The PARTNER study is a multicentre, two-arm, pragmatic cluster-randomised trial evaluating the impact of a focused and patient-centred cooperation between general practitioners (GPs) and community pharmacists (PARTNER intervention) on reductions in the use of psychotropic, sedative and anticholinergic potentially inappropriate medication (PSA-PIM) compared to a control intervention. The PARTNER intervention comprises (1) education for health care professionals, (2) an interprofessional workshop and case conference, (3) a pharmacy visit with brown bag/medication review and patient empowerment, (4) GP practice visit with shared decision making. The control intervention only comprises a pharmacy visit with brown bag review.
Aged 65 years or older
Patient is capable of giving consent
GP contact in the quarter prior to inclusion
Current use of ≥ 5 drugs, including ≥ 1 PSA-PIM (hypnotics, opioids, gabapentinoids, antipsychotics, antidepressants, anticholinergic urospasmolytics) with a treatment duration of ≥ 6 months
Terminal illness (life expectancy < 6 months)
Current treatment of pain associated with cancer
Other serious physical illness or mental distress (e.g. bereavement) that makes participation in the study impossible (according to the GP's assessment)
Psychiatric illness or addiction that makes participation in the study impossible (according to the GP's assessment)
Ludwig-Maximilians - University of Munich
Lead sponsor
Bielefeld University
Collaborator
University of Witten/Herdecke
Collaborator
University Hospital Heidelberg
Collaborator
University Hospital Regensburg
Collaborator
Institute for Applied Quality Improvement and Research in Health Care
Collaborator
Techniker Krankenkasse
Collaborator
Federal Joint Committee
Collaborator